Data from Study 2102-HEM-101 was initially presented at the American Society of Hematology 2022 meeting and led to the FDA approval of olutasidenib in December 2022 for relapsed refractory AML with IDH1 mutation. This evidence concerns the gene IDH1 and acute myeloid leukemia.